Atara Biotherapeutics shares rose more than 10 percent in early trading Nov. 7, after the company announced new filings and spending that came in lower than analyst expectations for the third quarter. The Thousand Oaks biotech firm said it had a net loss of around $72 million for the quarter ended Sept. 30, up from…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
